No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
INMB240719C7500
- 0.37
- +0.07+23.33%
15min DelayClose Jul 9 15:59 ET
0.37High0.30Low
0.30Open0.30Pre Close22 Volume237 Open Interest7.50Strike Price716.00Turnover356.34%IV0.90%PremiumJul 19, 2024Expiry Date0.30Intrinsic Value100Multiplier9DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type0.6416Delta0.0815Gamma4.05Leverage Ratio-0.0892Theta0.0008Rho2.60Eff Leverage0.0048Vega
Intraday
- 5D
- Daily
News
BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21
BTIG analyst Thomas Shrader maintains $INmune Bio(INMB.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate of 37.3% and a total ave
INmune Bio's Unique Alzheimer's Trial Endpoint Receives Validation
Express News | INmune Bio Inc: Interim Analysis, Performed by a Third-Party, Demonstrated No Need to Change Trial Design or Size
Express News | INmune Bio Inc: Planned Interim Analysis Confirms Accuracy of SAMPLE Size Calculations and Statistical Power for Emacc, Primary Endpoint
Express News | INmune Bio Completes Blinded Interim Analysis Of Its Phase II Alzheimer's Disease Trial, Says 'The Planned Interim Analysis Confirms the Accuracy of the Sample Size Calculations and Statistical Power for EMACC, the Primary Endpoint.'
Express News | INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
Comments
Gainers:
• $SpringWorks Therapeutics(SWTX.US$ +19.2% (Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase3DeFi Trial )
• $Roivant Sciences(ROIV.US$ +7.1% (FDA has approved VTAMA (tapinarof) cream)
• $Ocugen(OCGN.US$ +5.9% (announces that it is diversifying its innovative pipeline by introducing a Phase 3 cell therapy platform technology called Ne?Cart)
• $Skyline(SKY.US$ +4.4% (In reaction to earnings）
• $NetEase(NTES.US$ +4.1% (In...
• $SpringWorks Therapeutics(SWTX.US$ +19.2% (Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase3DeFi Trial )
• $Roivant Sciences(ROIV.US$ +7.1% (FDA has approved VTAMA (tapinarof) cream)
• $Ocugen(OCGN.US$ +5.9% (announces that it is diversifying its innovative pipeline by introducing a Phase 3 cell therapy platform technology called Ne?Cart)
• $Skyline(SKY.US$ +4.4% (In reaction to earnings）
• $NetEase(NTES.US$ +4.1% (In...
11
$INmune Bio(INMB.US$ Could this be better than $SAVA, let’s wait at see. Vested.
1
1
Read more